Fibrocell Science Inc

Fibrocell Science — Investor Presentation (October 2016)

20 slides from Fibrocell Science's investor presentation, Oct 5, 2016

  1. Slide 1: Corporate Presentation October 5, 2016

    Corporate Presentation October 5, 2016

  2. Slide 2: Forward-Looking Statements

    This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this purpose and include, among ot

  3. Slide 3: Company Highlights

    Company Highlights •Autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases of the skin and connective tissue •FCX-007 — Recessive Dystrophic Epidermolysis Bullosa (RDEB) Actively recruiting adult subjects; first human clinical data expect

  4. Slide 4: Key Advantages of Our Autologous Fibroblast Gene Therapy Platform

    Key Advantages of Our Autologous Fibroblast Gene Therapy Platform • Fibroblasts are the most common cell in skin and connective tissue, and are an ideal delivery vehicle to administer protein of interest locally  Localized administration avoids side effects typically associated with systemic therap

  5. Slide 5: Personalized Biologics Approach

    Personalized Biologics Approach 5

  6. Slide 6: Development Pipeline

    Development Pipeline 6 Personalized Biologic Indication Research Pre-Clinical Development Human Clinical Trials FCX-007 Recessive Dystrophic Epidermolysis Bullosa (RDEB) FCX-013 Linear Scleroderma Research Program Arthritis

  7. Slide 7: Recessive Dystrophic Epidermolysis Bullosa Disease, Current Treatments, Epidemiology

    Recessive Dystrophic Epidermolysis Bullosa 7 Disease Current Treatments Epidemiology • Cause: A mutation in the COL7A1 gene that encodes for COL7 • Devastating, progressive, painful blistering disease that often leads to death • Diagnosed at infancy • High mortality rate • Current treatments only ad

  8. Slide 8: FCX-007 Providing Hope for RDEB Patients

    FCX-007 Providing Hope for RDEB Patients 8 RDEB patients do not produce type VII collagen (COL7) due to mutation in COL7A1 gene Main component of anchoring fibrils that connect skin layers FCX-007 is an autologous human dermal fibroblast transduced with a lentiviral (LV) vector encoded for COL7A1 

  9. Slide 9: COL7 Expression Confirmation

    COL7 Expression Confirmation 9 Culture supernatant evaluated for in vitro COL7 expression • ELISA assay indicates virus dose-dependent protein expression • Trimeric form of COL7 produced by RDEB patient fibroblasts transduced with LV-COL7 •Must be trimeric to be functional Reference: Bruckner-Tuderm

  10. Slide 10: Detection of COL7 Expression by Immunofluorescence

    10 Detection of COL7 Expression by Immunofluorescence (Magnification 20x) • In vitro COL7 expression noted from FCX-007 replicates (red) • FCX-007 expresses higher levels of COL7 than normal human dermal fibroblasts (NHDF) as depicted by a brighter signal • No expression of COL7 in RDEB-positive fib

  11. Slide 11: Long-lasting COL7 Persistence Expected

    • Autologous cells minimize rejection risk • Direct administration of FCX-007 to the upper dermis ensures COL7 is expressed in the basement membrane zone where anchoring fibrils are formed • The integrative nature of the lentivirus allows the COL7A1 gene to be passed to daughter cells as FCX-007 cel

  12. Slide 12: FCX-007 Phase I/II Clinical Trial Design

    FCX-007 Phase I/II Clinical Trial Design 12 Title A Phase I/II Trial of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Objectives Primary 1) To evaluate the safety of FCX-007 Secondary 1) To evaluate mechanism of action of FCX

  13. Slide 13: Linear Scleroderma Disease, Epidemiology, Current Treatments

    Linear Scleroderma 13 Disease Epidemiology • Excess production of collagen I and III characterized by skin fibrosis and linear scars • The linear areas of skin thickening may extend to underlying tissue and muscle in children which may impair growth in affected legs and arms or forehead • Lesions ap

  14. Slide 14: FCX-013 Development Progressing

    FCX-013 Development Progressing 14 •Product profile Autologous fibroblasts genetically modified using lentivirus and encoded for a protein responsible for breaking down excess collagen I and III  Target protein known to breakdown collagens  Incorporates Intrexon’s RheoSwitch Therapeutic System® (

  15. Slide 15: FCX-013 Proof-of-Concept Study

    FCX-013 Proof-of-Concept Study 15 • Study Design  Bleomycin treated SCID mouse model  N=30 mice over test and control groups  Assessed histologically for reduction of dermal thickness and sub-dermal muscle in the presence of FCX-013 and oral ligand • Result  Bleomycin treatment resulted in skin

  16. Slide 16: RheoSwitch Control

    • FCX-013 employs Intrexon’s RheoSwitch Therapeutic System® (RTS®)  The RTS® biologic switch is activated by an orally- administered activator ligand (AL) that provides the ability to control level and timing of protein expression • Enhances the safety profile of FCX-013 by providing control over t

  17. Slide 17: Research Program for Arthritis

    Research Program for Arthritis 17 •Deliver therapeutic protein locally to the joint providing sustained efficacy while avoiding key side effects typically associated with systemic therapy •Combines Fibrocell’s autologous fibroblast technology with Intrexon’s cellular engineering to develop localized

  18. Slide 18: Milestones

    Milestones 18 Milestones Anticipated Timing FCX-007 1st Adult Subject Dosed Yearend 2016 FCX-007 Phase I/II Trial First human clinical data 3Q17 FCX-013 IND Submission 4Q17

  19. Slide 19: Company Highlights

    Company Highlights •Autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases of the skin and connective tissue •FCX-007 — Recessive Dystrophic Epidermolysis Bullosa (RDEB) Actively recruiting adult subjects; first human clinical data expect

  20. Slide 20: References

    References 1The Dystrophic Epidermolysis Research Association of America (DebRA). DEB brochure, page 6: http://www.debra.org/pdfs/Debra-of-America-Brochure.pdf; accessed 07/20/15. 2DEBRA International. What is EB Infographic: http://www.debra- international.org/epidermolysis-bullosa.html.; accessed

Fibrocell Science — Investor Presentation (October 2016) on 6ix